DDInter1570 DDInter462
Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities. Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.
Ranolazine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Dabrafenib
Ranolazine {u} (Compound) upregulates {v} (Gene) HIST2H2BE
HIST2H2BE {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Ranolazine {u} (Compound) causes {v} (Side Effect) Abdominal pain
Abdominal pain {u} (Side Effect) is caused by {v} (Compound) Dabrafenib
Ranolazine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dabrafenib
Ranolazine {u} (Compound) upregulates {v} (Gene) HIST2H2BE
HIST2H2BE {u} (Gene) is regulated by {v} (Gene) BRAF
BRAF {u} (Gene) is bound by {v} (Compound) Dabrafenib
Ranolazine {u} (Compound) causes {v} (Side Effect) Abdominal pain
Abdominal pain {u} (Side Effect) is caused by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dabrafenib
Ranolazine {u} (Compound) causes {v} (Side Effect) Electrocardiogram QT prolonged
Electrocardiogram QT prolonged {u} (Side Effect) is caused by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dabrafenib
Ranolazine {u} (Compound) resembles {v} (Compound) Guaifenesin
Guaifenesin {u} (Compound) causes {v} (Side Effect) Vomiting
Vomiting {u} (Side Effect) is caused by {v} (Compound) Dabrafenib
Ranolazine {u} (Compound) upregulates {v} (Gene) HIST2H2BE
HIST2H2BE {u} (Gene) regulates {v} (Gene) CDKN1A
CDKN1A {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Ranolazine {u} (Compound) resembles {v} (Compound) Bupivacaine
Bupivacaine {u} (Compound) resembles {v} (Compound) Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dabrafenib
Ranolazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dabrafenib (Compound)
Ranolazine (Compound) upregulates HIST2H2BE (Gene) and HIST2H2BE (Gene) is upregulated by Dabrafenib (Compound)
Ranolazine (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dabrafenib (Compound)
Ranolazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Dabrafenib
Ranolazine (Compound) upregulates HIST2H2BE (Gene) and HIST2H2BE (Gene) is regulated by BRAF (Gene) and BRAF (Gene) is bound by Dabrafenib (Compound)
Ranolazine (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Dabrafenib
Ranolazine (Compound) causes Electrocardiogram QT prolonged (Side Effect) and Electrocardiogram QT prolonged (Side Effect) is caused by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Ranolazine (Compound) resembles Guaifenesin (Compound) and Guaifenesin (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Dabrafenib (Compound)
Ranolazine (Compound) upregulates HIST2H2BE (Gene) and HIST2H2BE (Gene) regulates CDKN1A (Gene) and CDKN1A (Gene) is upregulated by Dabrafenib (Compound)
Ranolazine (Compound) resembles Bupivacaine (Compound) and Bupivacaine (Compound) resembles Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Dabrafenib